Headlines

GSK (GSK LN) discontinues camlipixant development in refractory chronic cough after CALM-2 did not reach statistical significance in the primary endpoint

Newsquawk Staff ·

GSK (GSK LN) discontinues camlipixant development in refractory chronic cough after CALM-2 did not reach statistical significance in the primary endpoint.

Sources

Related headlines